COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,137 Articles (22,693 medRxiv, 8,444 bioRxiv)

Most recent first Previous |  Page 1053: Articles 10521-10530  | Next

Performances of community pharmacists and community pharmacies during COVID-19 outbreak: a cross-sectional study
Sadeghinejad, A., Nikvarz, N.
10.1101/2021.12.14.21267818 — Posted: 2021-12-15
Real-world data on immune responses following heterologous prime-boost COVID-19 vaccination schedule with Pfizer and AstraZeneca vaccines in England
Westrop, S. J., Whitaker, H. J., Powell, A. A., Power, L., Whillock, C., Campbell, H., Simmons, R., Warrener, L., Ramsay, M. E., Ladhani, S. N., Brown, K. E., Amirthalingham, G.
10.1101/2021.12.14.21267562 — Posted: 2021-12-15
Global epidemiology of SARS-CoV-2 infection: a systematic review and meta-analysis of standardized population-based seroprevalence studies, Jan 2020-Oct 2021
Bergeri, I., Whelan, M., Ware, H., Subissi, L., Nardone, A., Lewis, H. C., Li, Z., Ma, X., Valenciano, M., Cheng, B., Al Ariqi, L., Rashidian, A., Okeibunor, J., Azim, T., Wijesinghe, P., Le, L.-V., Vaughan, A., Pebody, R., Vicari, A., Yan, T., Yanes-Lane, M., Cao, C., Cheng, M. P., Papenburg, J., Buckeridge, D., Bobrovitz, N., Arora, R. K., van Kerkhove, M. D., Unity Studies Collaborator Group
10.1101/2021.12.14.21267791 — Posted: 2021-12-15
Final sizes and durations of new COVID-19 pandemic waves in Poland and Germany predicted by generalized SIR model
Nesteruk, I.
10.1101/2021.12.14.21267771 — Posted: 2021-12-15
Differential Risk of SARS-CoV-2 Infection by Occupation: Evidence from the Virus Watch prospective cohort study in England and Wales
Beale, S., Hoskins, S. J., Byrne, T. E., Fong, E. W. L., Fragaszy, E., Geismar, C., Kovar, J., Navaratnam, A. M., Nguyen, V., Patel, P., Yavlinsky, A., Johnson, A., Aldridge, R. W., Hayward, A.
10.1101/2021.12.14.21267460 — Posted: 2021-12-15
Comparison of the Immunogenicity of five COVID-19 vaccines in Sri Lanka
Jeewandara, C., Aberathna, I., Danasekara, S., Gomes, L., Fernando, S., Guruge, D., Ranasinghe, T., Gunasekara, B., Kamaladasa, A., Kuruppu, H., Somathilaka, G., Jayamali, J., Jayathilaka, D., Wijayathilake, H., Pushpakumara, P., Harvie, M., Nimasha, T., de Silva, S., Wijayamuni, R., Schimanski, L., Rijal, P., Tan, J., Townsend, A., Ogg, G., Malavige, G. N.
10.1101/2021.12.15.21267834 — Posted: 2021-12-15
Anti-SARS-CoV-2 cellular immunity in 571 vaccinees assessed using an interferon-γ release assay
Uwamino, Y., Wakui, M., Yatabe, Y., Nakagawa, T., Sakai, A., Kurafuji, T., Shibata, A., Tomita, Y., Noguchi, M., Tanabe, A., Arai, T., Ohno, A., Yokota, H., Uno, S., Yamasawa, W., Sato, Y., Ikeda, M., Yoshimura, A., Hasegawa, N., Saya, H., Murata, M.
10.1101/2021.12.14.21267039 — Posted: 2021-12-15
COVID-19 and Indian population: a comparative genetic analysis
Patil, S., Pemmasani, S. K., Chitturi, N., Bhatnagar, I., Acharya, A., Subash, L. V.
10.1101/2021.12.15.21267816 — Posted: 2021-12-15
Impact Of an Immune Modulator Mycobacterium-w On Adaptive Natural Killer Cells and Protection Against COVID-19
Jaiswal, S. R., Arunachalam, J., Saifullah, A., Mehta, A., Bhagawati, G., Lakhchaura, R., Aiyer, H., Research & Development, Cadila Pharmaceuticals Ltd, Ahmedabad., , Chakrabarti, S.
10.1101/2021.12.14.21267696 — Posted: 2021-12-15
COVID-19 vaccination, from first dose to booster: New insights into the frequency of most common systemic adverse events and possible booster nocebo effects based on a systematic review
Behrens, C., Samii-Moghadam, M., Gasperazzo, T., Gross, A. M., Mitchell, J., Lampe, J. B.
10.1101/2021.12.15.21267847 — Posted: 2021-12-15

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).